Atropos Health has been recognized as one of the world's 100 most promising private artificial intelligence companies by CB Insights, earning a spot on the prestigious annual AI 100 list. The healthcare AI company joins a select group of early and mid-stage startups identified as leaders in applying artificial intelligence across various industries and architectures.
"The AI 100 winners are future movers and shakers, taking big swings that will shape the future of AI," said Manlio Carrelli, CEO at CB Insights. "This year's cohort is pushing AI applications from emerging to emerged, working on everything from AI agents for complex processes to security and robotics. They've also zeroed in on new and promising technologies that might not be on the radar of many enterprises — multi-agent systems, novel computing and data curation approaches, and physical AI."
The recognition comes during a significant growth period for Atropos Health, which raised $33 million in Series B funding over the past year to scale its automation of high-quality, personalized real-world evidence. The company has expanded its Atropos Evidence™ Network to include over 300 million patient records, making it the largest federated data network in healthcare.
"Atropos Health is proud to be part of the CB Insights AI 100 as we continue to drive the adoption of AI technology into practical use in healthcare and research around evidence generation," said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health.
A key innovation from the company is ChatRWD®, a generative AI tool that dramatically reduces the time required to produce publication-grade real-world evidence from months to minutes. An independent study found that ChatRWD outperformed other large language models (LLMs), completing 94 percent of answers and delivering the best responses for novel questions in 87 percent of cases.
The 2025 AI 100 cohort represents a diverse group of companies, with nearly 75% being early-stage ventures (Series A or earlier). Collectively, these organizations have raised $11.4 billion in equity funding over time, including more than $2.3 billion in 2025 alone. The list includes 27 companies based outside the United States, spanning 13 countries.
Atropos Health develops GENEVA OS™, described as "the operating system for rapid healthcare evidence" that operates across its real-world data network. The company works with healthcare and life science organizations to close evidence gaps and improve patient outcomes through data-driven care while expediting research that advances medicine.
Click here for the original news story.